Amgen's new meds beat estimates as anemia drugs slip

Amgen's ($AMGN) anemia drugs faltered again in the fourth quarter with sales declining 15% on Aranesp and 18% on Epogen. New bone drugs Xgeva and Prolia beat analyst estimates for their first full year on the market with $554 million in sales. Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…